Preferred Label : Acasunlimab;
NCIt synonyms : DuoBody PD-L1 x 4-1BB GEN1046; Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046;
NCIt definition : A recombinant, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting
both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis
factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory,
immunostimulating and antineoplastic activities. Upon administration, acasunlimab
simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte
subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Through
4-1BB binding, acasunlimab acts as a conditional 4-1BB agonist, resulting in T-cell
co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same
time, acasunlimab prevents PD-L1 from binding to and activating its receptor, programmed
cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition,
activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor
cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on
activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses
the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of
the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor
that plays a key role in T-cell proliferation, survival and cytolytic activity.;
UNII : H52ITZ9X9D;
CAS number : 2253937-12-9;
Molecule name : BNT 311; GEN-1046; GEN 1046;
NCI Metathesaurus CUI : CL1406283;
Origin ID : C172194;
UMLS CUI : C5706673;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
